Downtrend on the daily chart: below its 50-day average · SuperTrend down since Jun 11 · below the Ichimoku cloud · RSI 21 (oversold) · MACD below its signal · 6% above its 52-week low
None of the 29 investors followed here reported a position in OPTH in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a OPTH trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 28, 2026 | Pump (Melanie)Director of Issuer | — | 0 | — |
| Aug 31, 2026 | Stevens (Dane Nicholas)Director of Issuer | Acquisition in the public market at price 4.99 per share. | 5K | $24.95K |
| Aug 4, 2026 | Stevens (Dane Nicholas)Director of Issuer | Acquisition in the public market at price 4.75 per share. | 3.8K | $18.05K |
| Jul 15, 2026 | Stevens (Dane Nicholas)Director of Issuer | Acquisition in the public market at price 4.95 per share. | 3K | $14.85K |
| Jul 15, 2026 | Stevens (Dane Nicholas)Director of Issuer | Acquisition in the public market at price 4.93 per share. | 700 | $3.45K |
| Jul 14, 2026 | Stevens (Dane Nicholas)Director of Issuer | Acquisition in the public market at price 4.49 per share. | 15K | $67.41K |
| May 18, 2026 | Hodges (Leah)Senior Officer of Issuer | — | 10.2K | — |
| May 18, 2026 | Mosberian (Jason)Director of Issuer | — | 25.4K | — |
| May 18, 2026 | Safarik (Bryan Edward)Director of Issuer | — | 263.5K | — |
| May 18, 2026 | Safarik (Bryan Edward)Director of Issuer | — | 20.1K | — |
| May 18, 2026 | Safarik (Bryan Edward)Director of Issuer | — | 19.3K | — |
| May 18, 2026 | Safarik (Bryan Edward)Director of Issuer | — | 38.7K | — |
| May 18, 2026 | Safarik (Jacob Frederick)Director of Issuer | — | 105.5K | — |
| May 18, 2026 | Stevens (Dane Nicholas)Director of Issuer | — | 12.58M | — |
| May 18, 2026 | Wilson (John James)Director of Issuer | — | 653.5K | — |
| May 18, 2026 | Wilson (John James)Director of Issuer | — | 7.31M | — |
| Mar 26, 2026 | Safarik (Bryan Edward)Director of Issuer | Acquisition in the public market at price 0.21 per share. | 4K | $836 |
| Mar 17, 2026 | Stevens (Dane Nicholas)Director of Issuer | Acquisition in the public market at price 0.21 per share. | 100K | $20.80K |
| Mar 17, 2026 | Stevens (Dane Nicholas)Director of Issuer | Acquisition in the public market at price 0.20 per share. | 100K | $20.40K |
| Feb 12, 2026 | Stevens (Dane Nicholas)Director of Issuer | Acquisition in the public market at price 0.25 per share. | 70K | $17.50K |
No analyst coverage for this instrument.
Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company also engages in farming, processing, and distribution of raw mushroom biomass, mushroom extracts, manufacturing of drug products, and mushroom supplements. It sells its products through Amazon marketplace and distributors/brokers, as well as online. Optimi Health Corp. was incorporated in 2020 and is based in Princeton, Canada.